search innovation
A NEW DRUG FOR THE PREVENTION AND TREATMENT OF HERPES SIMPLEX VIRUS (HSV-1)
keywords: herpes, simplex, HSV-1, drug, infection, biochemistry, biophysics, botechnology
offer number: 328

Herpes simplex virus 1 (HSV-1), is one of the most commonly encountered pathogens in humans. The most recent statistics indicate that approximately 50-90% of the world population is HSV-1 seropositive. The most common primary infections are cold sores occurring mainly on the face (especially the skin, tongue and lips). However, infection with HSV-1 may also lead to severe diseases such as inflammation of the eye or encephalitis. These diseases are characterized by severe course and may cause permanent adverse health effects (e.g. blindness), and even death.


Currently, there are several antiviral drugs, which are active against pathogens belonging to the Herpesviridae family. These drugs reduce the frequency and severity of relapses and also alleviate bothersome symptoms during the primary infection. Although they are usually only effective for the initial infection, they do not eliminate a virus in a latent state and thus do not protect a person before re-emergence of symptoms. There has also been increasing emergence of drug resistant viral strains. Thus, there is a need to find a new approach to developing effective treatment of HSV-1 infection. The new invention of the Jagiellonian University, which is the subject of the proposed offer, discloses a new drug for treatment of herpes simplex virus (HSV-1) infection.

 

The main advantages of the offered drug are:

  • confirmed ability to efficient bind of herpes simplex virus (HSV-1) and inhibit its replication in vitro,
  • low-toxicity of the drug in vitro,
  • the possibility to apply as an ointment or solution administrated either topically to the skin or eye, orally, intraperitoneally or intravenously.

 

The offered invention is subject of a patent application. Further research and development are conducted at the Faculty of Chemistry and Faculty of Biochemistry, Biophysics and Biotechnology of the JagiellonianUniversity. Currently, the Centre for Technology Transfer CITTRU is looking for partners interested in the development of the invention and its commercial application.

commercial utility: prevention and treatment of herpes simplex virus (HSV-1)
field of science: biochemistry, biophysics, biology, medical biology, microbiology, biotechnology
forms of protection: patent application
technological maturity: demanding R & D
property rights: Jagiellonian University
variants of cooperation: license, consulting, spin-off company, comercial contract research, sale

information / broker of Jagiellonian University

name and surname: Klaudia Polakowska, PhD
phone number: +48 12 664 42 13, +48 519 329 129
NEWS
latest information
JU scientists to develop biological agricultural support solutions
The project “Interactions between plants and microorganisms in response to the presence of potentially toxic metals, metalloids and silicon (Si)” by Prof. Katarzyna Turnau from the JU Faculty of Biology won a grant from the Polish National Agency for Academic Exchange. The study aimed at replacing the widespread use of agrochemicals with biological agricultural support solutions will also involve researchers from Slovakia and Austria.
JU students will help people suffering from depression
Therapify is a mobile application designed to help depressed people. It was first conceived by Łukasz Pstrong, a graduate of the AGH University of Science and Technology in Kraków, and developed over the course of the last two years with collaborators from his university, the Jagiellonian University, and SWPS University of Social Sciences and Humanities in Warsaw.
Plakaty Demo Day II +
In January, we complete the project managed by CTT CITTRU as part of the program of the Ministry of Science and Higher Education - Incubator of Innovation +. We supported, among others, 18 research teams selected in the competition, that develop innovative technologies. Thanks to the funds granted by CTT CITTRU and hard work of technology transfer officers, pre-implementation research was financed, which increased the attractiveness of these inventions and investors interest in them. Take look at the gallery of posters for technologies, developed as part of the project. What do you think about it
CITTRU team
Our employees
PARTNERS
Innovation Forum KrakówKlaster Lifescience KrakówWolves SummitPACTTJagiellońskie Centrum Innowacji
Contact
GET IN TOUCH WITH US
Centre for Technology Transfer CITTRU
Jagiellonian University in Kraków - POLAND
ul. Bobrzyńskiego 14,
30-348 Kraków

PHONE:
+48 12 664 42 00
E-MAIL:
cittru@uj.edu.pl
Fundusze EuropejskieMNiSWInkubator InnowacyjnościUnia Europejska